Based on the Cidara Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Cidara Therapeutics Inc is USD 27.17 over the next 12 months. Cidara Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cidara Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Cidara Therapeutics Inc’s stock price was USD 11.30. Cidara Therapeutics Inc’s stock price has changed by +5.21% over the past week, +3.96% over the past month and +1,243.48% over the last year.
No recent analyst target price found for Cidara Therapeutics Inc
No recent average analyst rating found for Cidara Therapeutics Inc
Company Overview Cidara Therapeutics Inc
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. Read Less
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and ...Read More
Frequently Asked Questions About Cidara Therapeutics Inc (CDTX) Stock
Based on ratings from 3 analysts Cidara Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on CDTX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for CDTX is USD 27.17 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 24.
Unfortunately we do not have enough data on CDTX's stock to indicate if its overvalued.
The last closing price of CDTX's stock was USD 11.30.
The most recent market capitalization for CDTX is USD 0.08B.
Based on targets from 3 analysts, the average taret price for CDTX is projected at USD 27.17 over the next 12 months.
This means that CDTX's stock price may go up by +140.41% over the next 12 months.
We can't find any ETFs which contains Cidara Therapeutics Inc's stock.
As per our most recent records Cidara Therapeutics Inc has 69 Employees.
Cidara Therapeutics Inc's registered address is 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121.
You can get more information about it from Cidara Therapeutics Inc's website at https://www.cidara.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Cidara Therapeutics Inc (CDTX) Stock
Based on ratings from 3 analysts Cidara Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on CDTX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for CDTX is USD 27.17 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 24.
Unfortunately we do not have enough data on CDTX's stock to indicate if its overvalued.
The last closing price of CDTX's stock was USD 11.30.
The most recent market capitalization for CDTX is USD 0.08B.
Based on targets from 3 analysts, the average taret price for CDTX is projected at USD 27.17 over the next 12 months.
This means that CDTX's stock price may go up by +140.41% over the next 12 months.
We can't find any ETFs which contains Cidara Therapeutics Inc's stock.
As per our most recent records Cidara Therapeutics Inc has 69 Employees.
Cidara Therapeutics Inc's registered address is 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121.
You can get more information about it from Cidara Therapeutics Inc's website at https://www.cidara.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CDTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
